<DOC>
	<DOCNO>NCT00120003</DOCNO>
	<brief_summary>The purpose trial ass whether blood pressure lower agent candesartan ( angiotensin receptor type 1 blocker ) effective give patient acute stroke elevated blood pressure . Hypothesis : AT1 receptor blockade candesartan acute stroke : 1. reduce risk death major disability 6 month 6 % absolute risk reduction , relative placebo . 2. reduce risk combine event `` vascular '' death , myocardial infarction , stroke first 6 month 25 % relative risk reduction , relative placebo</brief_summary>
	<brief_title>Scandinavian Candesartan Acute Stroke Trial ( SCAST )</brief_title>
	<detailed_description>It long controversy whether elevate blood pressure lower acute phase stroke . Current clinical practice generally accept high blood pressure acute phase stroke , avoid reduction cerebral blood perfusion . This practice well-founded theoretical basis , support evidence clinical trial . The newly publish study ACCESS ( Stroke 2003 ; 34:1699 ) show clear beneficial effect angiotensin receptor blocker candesartan acute phase stroke , trial seriously underpowered . The Scandinavian Candesartan Acute Stroke Trial ( SCAST ) design provide reliable data effect candesartan wide variety patient acute stroke ( target recruitment 2,500 ) . Patients present acute stroke ( &lt; 30 hour ) systolic blood pressure ≥140 mm Hg randomly assign candesartan 4 16 mg daily match placebo 7 day , follow candesartan treatment 6 month patient hypertensive end treatment period ( clinician 's discretion ) . Follow-up perform double-blind 30 day , 3 month 6 month . The trial co-ordinated Ullevaal University Hospital Oslo , Norway . Over 100 centre Norway , Sweden , Denmark Belgium agree participate . Financial contributor : The Eastern Norway Regional Health Authority , AstraZeneca , Ullevaal University Hospital ( Oslo ) . AstraZeneca supply drug placebo trial .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Clinical stroke syndrome limb paresis , likely represent transient ischaemic attack nonstroke pathology ( e.g . cerebral tumour ) Systolic blood pressure ≥ 140 mm Hg Trial treatment possible within 30 hrs symptom onset . If time onset know , use time patient last know well . Consent ( subsidiary , assent legal acceptable representative , waiver consent ) Age &gt; 18 year Markedly reduce consciousness ( i.e . Scandinavian Stroke Scale consciousness score ≤ 2 ) Patient already receive AT1 receptor blocker Contraindication treatment AT1 receptor blocker , e.g . : know renal failure ( woman : creatinine ≥ 150 µmol/L ; men : ≥ 180 µmol/L ) previously diagnose bilateral renal artery stenosis previously diagnose highgrade aortic stenosis previously diagnose seriously impair liver function and/or cholestasis know intolerance candesartan tablet ingredient Clear indication , clinician 's view , start treatment AT1 receptor blocker treatment period ( e.g . chronic heart failure grade IIIIV , presence intolerance ACE inhibitor ) Clear indication , clinician 's view , antihypertensive therapy acute phase stroke ( i.e . concurrent hypertensive encephalopathy aortic dissection , situation ) Other serious lifethreatening disease stroke : Patient severely mentally physically disabled ( e.g . Mini Mental Status score &lt; 20 , modify Rankin Scale score ≥ 4 ) Life expectancy &lt; 12 month Patient unavailable followup ( e.g . fixed address ) Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Acute stroke</keyword>
	<keyword>Elevated blood pressure</keyword>
	<keyword>Blood pressure lower treatment</keyword>
</DOC>